Follow-On Biologics Bill’s Prospects Are Uncertain, Waxman Staffer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Busy House committee schedule and “fractured” Senate will make reaching consensus a challenge, Ann Witt says, but potential inclusion of FOBs into health reform bill is “wildcard.”